The effects of atorvastatin treatment on the mean platelet volume and red cell distribution width in patients with dyslipoproteinemia and comparison with plasma atherogenicity indicators--A pilot study
Language English Country United States Media print-electronic
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
25727667
DOI
10.1016/j.clinbiochem.2015.02.010
PII: S0009-9120(15)00064-8
Knihovny.cz E-resources
- Keywords
- Atherogenic dyslipidaemia, Atorvastatin, Dense LDL, Mean platelet volume, Red cell distribution width, Small,
- MeSH
- Anticholesteremic Agents therapeutic use MeSH
- Apolipoprotein A-I blood MeSH
- Apolipoprotein B-100 blood MeSH
- Atherosclerosis blood MeSH
- Atorvastatin therapeutic use MeSH
- Dyslipidemias blood drug therapy MeSH
- Erythrocyte Indices drug effects MeSH
- Middle Aged MeSH
- Humans MeSH
- Pilot Projects MeSH
- Aged MeSH
- Mean Platelet Volume * MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Anticholesteremic Agents MeSH
- APOA1 protein, human MeSH Browser
- APOB protein, human MeSH Browser
- Apolipoprotein A-I MeSH
- Apolipoprotein B-100 MeSH
- Atorvastatin MeSH
OBJECTIVES: The mean platelet volume (MPV) and red cell distribution width (RDW) have recently arisen interest because of their association with an increased cardiovascular risk. The aim of our study was, therefore, to determine whether an association exists between MPV, RDW and lipoprotein sub-fractions, and to show the impact of statin therapy on these new possible biomarkers of atherosclerotic risk. DESIGN AND METHODS: A cohort of 40 patients with hypercholesterolaemia (29 females, mean age 62.9±9 years), without previous hypolipidaemic treatment were enrolled. The patients were treated with atorvastatin 40 mg/day for 12 weeks. Total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density cholesterol (HDL-C), triglycerides (TG), LDL-C sub-fractions [large LDL-C 1-2 and small dense (sd)-LDL-C 3-7], apolipoproteins (apoA1, apoB), apoB/apoA1 ratio, atherogenic index of plasma (AIP), haematological parameters (including MPV, RDW) and safety parameters (renal, hepatic) were measured before and after 12 weeks of atorvastatin treatment. RESULTS: At baseline, a strong correlation between HDL-C, TG, sd-LDL-C, apoB, apoB/apoA1, and AIP with MPV (r=-0.55, p<0.001; r=0.57, p<0.001; r=0.73, p<0.001; r=0.41, p<0.05; r=0.52, p<0.001; r=0.61, p<0.001, respectively) and RDW (r=-0.49, p<0.001; r=0.62, p<0.001; r=0.67, p<0.001; r=0.41, p<0.05; r=0.43, p<0.05; r=0.65, p<0.001, respectively) was found. After 12 weeks of treatment with atorvastatin, MPV and RDW values underwent significant modification only in those patients displaying the strongest lipid-lowering effect. CONCLUSIONS: Values of MPV and RDW seem to reflect a pro-atherogenic lipoprotein profile mainly represented by the presence of sd-LDL-C.
Central University Hospital of Asturias Oviedo Asturias Spain
Clinica Medica 1 Fondazione IRCCS Policlinico San Matteo Università degli Studi di Pavia Italy
References provided by Crossref.org
